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for income was higher than that of health. In all cases, as often observed, hyper-
bolic discounting characterised by decreasing rate over increasing delay, was ob-
served.
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OBJECTIVES: In 2011-12, the cost-effectiveness of imatinib, dasatinib and nilotinib
for 1st-line chronic myeloid leukaemia in the UK was evaluated by NICE. We discuss
three methodological issues which strongly influence the estimated cost-effective-
ness of these drugs. These issues are also important for the cost-effectiveness of
many other drugs and medical devices.METHODS:We discuss the pros and cons of
the following competing methods. 1) Estimation of overall survival: Method A:
estimated as the cumulative duration of 1st-, 2nd- and 3rd-lines of treatments.
Method B: estimated from the surrogate responses: complete cytogenetic response
and major molecular response; 2) Cost-effectiveness of subsequent treatments: the
cost-effectiveness of 1st-line drugs are substantially affected by the cost-effective-
ness of subsequent drugs. Method A: traditional method of modelling estimated
costs and QALYs of subsequent drugs. Alternatively, minimise impact of cost-
effectiveness of subsequent treatments by either Method B: setting per patient
costs and QALYs of subsequent treatments equal between treatment arms, or
Method C: cap the cost-effectiveness ratio whilst on subsequent treatments at the
willingness to pay threshold; 3) Future drug prices: This is an important issue given
that the patent for imatinib will expire soon, in 2016, after which its price may fall
substantially. Method A: use the current list prices of all drugs in the future, as
required by NICE. Method B: assume constant drug prices until patent expiry, at
which time assume a fixed price cut. Assuming a modest 25% price cut on patent
expiry, the ICER for nilotinib vs. imatinib increases substantially, from £36,000 to
£54,000 per QALY. RESULTS: The pros and cons of the various methods are
discussed. CONCLUSIONS: This study informs important methodological issues
which apply to many health technologies. The study ultimately contributes to
more accurate assessments of the cost-effectiveness of health technologies, and
hence whether a given technology should be publicly-funded.
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OBJECTIVES: Cardiovascular disease is the leading cause of death in Germany. For
a better communication of the individual risk profile, a group of researchers of the
University of Marburg developed ARRIBA, a tool for a better communication be-
tween the general practitioners and the patient, that reports the individual 10-year
probability of a cardiovascular event. To further enhance communication and to
include lifetime risk and time-to-event estimates in this tool, we developed and
validated a state-transition microsimultion model (STMM). The focus of this pre-
sentation is on the validation of our model. METHODS: Our STMM was validated
against the results from a US observational multi-cohort study (Berry et al., 2012)
This study included data from 18 cohort studies with a total of 257,384 subjects and
estimated the lifetime risk of cardiovascular events. Our STMM was populated with
28 cohorts closely matching 7 risk profiles and 4 age groups of the observational
study and was evaluated for the time period of data collection in the observational
study. Projected outcomes were proportion experiencing myocardial infarction,
stroke, cardiovascular death, or any cardiovascular event. These outcomes were
compared to the observed outcomes. RESULTS: When comparing the lifetime risk
of experiencing any cardiovascular event estimated by the model to the observed
data, 15 and 14 of the 28 cohorts were within the 95% confidence intervals of the
observed results for men and women, respectively. The other estimates were
within two and a half times this range. Although the observational study was a
useful source for validation, the validation process was challenging with respect to
matching cohorts and outcomes. One issue is whether a validation to a US cohort
study is suitable for a European model. CONCLUSIONS: External validation in-
creased our confidence in the microsimulation model. When comparable European
data become available the validation will be repeated.
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OBJECTIVES: The memory-less feature of Markov models can be a limiting factor
when treatment-sequencing needs to be modeled and the transition probability in
second- and subsequent-line treatments are not constant. Although tunnel-states
are commonly used to model time-dependency, they can become unruly. Hence,
patient simulation models and/ or sophisticated software packages such as R are
required to model complex time dependency. An alternate method of using nested
markov models was presented at a previous conference to model time-dependency
in treatment sequence for a hypothetical model in Excel. This method is now
applied to a published model in epilepsy and results are validated using real data.
METHODS: The Wilby 2004 epilepsy model is used as a reference to derive model
inputs and validate results. It is a probabilistic treatment sequencing decision
model in epilepsy implemented using R. The nested markov method involves first
disaggregating the model by treatment, then combining the net present values of
each treatment into the treatment sequence by weighting proportional to the time
spent in the sequence, lastly followed by further discounting to account for place-
ment in the sequence. Results obtained using the nested markov methods are
validated with those published in Wilby 2004.RESULTS:Quality-adjusted life-years
obtained with the nested Markov modeling approach were similar and were within
the confidence intervals of results obtained by Wilby 2004. CONCLUSIONS: Nested
markov models can be a simple alternative to model time-dependency if transpar-
ency and less intense computational programming are required. It represents a
straightforward and intuitive approach to modeling a fixed treatment sequence,
however, it may not be suitable if the position in a sequence is inter-changeable,
and treatment effectiveness depends on the position in a sequence (e.g. cancer
therapies where disease progression impacts treatment effectiveness).
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OBJECTIVES: To assess the long-term burden of asthma in children with allergic
rhinitis/conjunctivitis. METHODS: We reviewed the literature on incidence of
asthma in patients with allergy. Furthermore we estimated long-term outcomes
associated with allergic rhinitis/conjunctivitis in children using a Markov health
state model. The model was populated using data from a long-term prospective
follow-up, where asthma status was recorded up to 10 years in patients receiving
only symptomatic treatment for allergy and asthma symptoms. The model was
used to explore the impact of key drivers of long-term patient outcomes. Burden to
patient was measured as the difference between net present value of QALYs and
life-years. RESULTS: Allergic rhinitis/conjunctivitis in childhood is associated with
a risk of developing asthma. The asthma risk is highest at younger age and de-
creases as the child reaches adolescence and adult age. Furthermore, allergic rhi-
nitis is a risk factor for childhood allergic asthma to persist into middle age. The
model analysis showed that in per one hundred 10-year old patients with hay fever,
but no previous asthma: 57 will develop asthma over a 10 years horizon; In total 55
QALYs are lost over a 10 years horizon of which 67% is attributable to allergic
asthma; and Additional 23 respectively 43 QALYs are lost when analyzing on a 15
respectively 20 years horizon even when assuming no additional cases occur after
year 10.CONCLUSIONS:Childhood allergic rhinitis is a risk factor for developing allergic
asthma in childhood/ preadolescence. Allergic asthma in turn has a pro-found effect on
the long-term burden of allergic rhinitis/conjunctivitis. Literature suggests that childhood
asthma may impact on quality of life also when the patient reaches middle age. Taken
together this suggests a large potential for specific immunotherapy with disease-modify-
ing properties to reduce the burden of allergy and allergic asthma.
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OBJECTIVES: Bayesian mixed treatment comparison models (MTCs) provide a
powerful methodology to obtain estimates of relative efficacy between alternative
treatments when head to head evidence is not available or not sufficient. Most
evaluations only consider evidence from randomized controlled trials (RCTs),
while information from other trial designs is ignored. In this work we propose 3
methods to extend MTC models to systematically include evidence from different
trial designs using an application in Rheumatoid Arthritis (RA). METHODS: A sys-
tematic literature review identified 13 RCTs and 3 observational trials assessing the
treatment effects of five anti-TNF agents currently licensed in Europe. Naïve Pool-
ing does not differentiate between designs, one simply pools across all studies. It is
not possible to down-weight designs of lesser quality or to adjust for bias. Alterna-
tively observational data can be analysed separately and the results used to inform
the prior distribution for the RCT model. This allows for bias adjustments and
controlling the influence on the overall effect. In addition to that, a 3-level hierar-
chical model allows the direct comparison of estimates on study type level to
overall level. The method accounts for between trial design heterogeneity; overall
estimates become more conservative when study type estimates differ. RESULTS:
Including evidence from observational trials to estimate the relative efficacy be-
tween anti-TNF agents in RA has strengthened our belief in the effect estimates.
Overall, the observational trial data found less difference between the agents than
was suggested by RCT evidence only. CONCLUSIONS: Observational data is avail-
able for many disease areas providing additional information on treatment effec-
tiveness. We think it is important for an informed decision making process to
include all available evidence. The proposed techniques provide a framework for
systematically including evidence from different trial designs in a MTC model.
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OBJECTIVES: To demonstrate a simplified approach to cost-effectiveness analysis
of new diagnostic tests based on minimal information and without developing a
full decision-analytic modeling framework, which is often complex, time consum-
ing and potentially inefficient. METHODS: Using a simplified decision-analytic ap-
proach to the complete pathway of care from diagnosis to subsequent treatment,
cost-effectiveness of the new diagnostic test is expressed as a mathematical func-
tion of diagnostic accuracy, cost, burden, and the cost-effectiveness of treatment.
This function only includes parameters available during early test development
phases and does not require any simulation. Parameter uncertainty is accounted
for by applying probabilistic sensitivity analysis. In a clinical example, the cost-
effectiveness of magnetic resonance angiography (MRA) compared with digital
subtraction angiography (DSA) for the detection of new intracranial aneurysms is
assessed in patients with previous subarachnoid hemorrhage. RESULTS: The sim-
plified approach produced cost-effectiveness results for MRA compared with DSA
in line with our previous and similar, but much more comprehensive assessment.
The comprehensive assessment resulted in a net monetary benefit (NMB) of $1,910
(95%CI 1,809 to 5,565) and probabilities of effectiveness and cost-effectiveness of
98% and 87%, respectively (Willingness-to-pay threshold $50,000 per QALY). Our
simplified approach returned a NMB of $1,779 (95%CI 1,170 to 2,477) with corre-
sponding probabilities of effectiveness and cost-effectiveness of 100% and 98%,
respectively. Hence, the simplified approach would already have provided a clear
indication of the potential benefits of replacing DSA with MRA. CONCLUSIONS:
Given the abundance of new diagnostic tests an approximation of the cost-effec-
tiveness of new tests at minimal costs is highly valuable. Our low-cost mathemat-
ical satisficing approach supports improved use of health care resources by indi-
cating 1) which tests are promising; 2) which tests are not promising; and 3) which
tests require more rigorous economic evaluations to obtain improved estimates of
cost-effectiveness but at a higher use of health care resources.
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OBJECTIVES: To present an effective and elegant model approach to deal with
specific characteristics of complex modeling. METHODS: A discrete event simula-
tion (DES) model with multiple complications and multiple outcomes that each can
occur simultaneously was developed. In this DES model parameters, attributes and
distributions were estimated based on patient population (patient-level DES
model). Next to this, the DES model was constructed in such a way that it is par-
ticularly capable to deal with: different disease states, multiple complications, and
multiple long-term outcomes. Our model was designed for comparing two radia-
tion treatments (photon vs. proton) for head and neck cancer. In this model the
following elements were included: different disease states (local recurrency, dis-
tance metastasis, and combinations), simultaneous complications (xerostomia,
sticky saliva, dysphagia, and thyroid dysfunction), and multiple long-term out-
comes (overall survival, quality of life, costs). Estimates were based on the patient
population (n1013) treated with radiation therapy for head and neck tumor and
combined with literature based estimates. RESULTS: The following discrete events
were scheduled by a so-called statechart (system of graphical specification): pri-
mary tumor, mortality, time-to-event, and disease states. These events are sched-
uled with transitions following distributions that depend on tumor and other pa-
tient characteristics. In addition, the model contains a module for the primary
tumor prognosis, and separate, parallel modules/events for each important com-
plication. Costs and values of health for the different states/complications and
combined to cost-effectiveness are included. CONCLUSIONS: This elaborated DES
model allows multiple complications and outcomes to be modeled in parallel and
is suited to estimate the long-term effects. The global structure of our model can be
interesting for modeling other diseases that are associated with complex treat-
ment regimes and multiple complications. In addition, side effects in parallel to
main effects can be modeled and multiple outcomes of new pharmaceuticals com-
pared to current medication.
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OBJECTIVES: To identify the possible problems and trends regarding health eco-
nomic modelling in Hungarian Health Technology Assessment. We were especially
interested in the general quality of health economic models. METHODS: We ana-
lyzed the submissions which were based on a health economic model, which were
assessed by the Hungarian HTA Office since 2004. We created a database in which
we summed up our findings: the type of the model, the quality and robustness of
the model, the type of disease which was modelled. We sorted the models by these
criteria and searched for correlations. We attempted to set some indicators regard-
ing the quality of models. We also analysed some methodological and procedural
problems from multiple aspects related to modelling in Hungary. RESULTS: Our
findings show that the use of health economic models is increasing and that most
of the models are decision tree and Markov types. The submitted Markov models
are from the subtype of Markov chain models with only a few exceptions. Primarily
simulation models are only used in a small share of submissions (11%), especially
in the cases of chronic diseases. Trends show that the proportion of Markov models
which have probabilistic sensitivity analyses are also increasing (from 0% to nearly
30%). The submitted models became more detailed and they show a distinct im-
provement in methodology during the past 8 years. These factors indicate the
general improvement of the quality of Hungarian health economic modelling.
CONCLUSIONS: Although it is not compulsory in Hungary, more and more manu-
facturers present or submit health economic models to the Department of Health
Technology Assessment. Based on our findings, several factors indicate that the
submitted models are getting more detailed, and better of quality.
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OBJECTIVES: To compare the computation speed when running a microsimulation
model and probabilistic sensitivity analysis (PSA) on four widely-available pro-
gramming platforms: Excel, Visual Basic for Applications (VBA), R, and Java.
METHODS: A simple microsimulation model predicting the number of handouts
collected by 2500 ISPOR attendees during a congress was created to test efficiency
measured by model running speed. Speed was based on the system time and
included only the portion of code used to run the model, excluding any code for
parameter input or output. Calculations were performed on a computer running
Windows 7, dual core 2.6 GHz processor, with 4 GB RAM. All platforms except Excel
were cross-validated by using a list of pseudo-random numbers as model inputs to
ensure consistency of model outputs. PSA was conducted by sampling random
probabilities from beta distributions and replicating the model 1000 times. Ten
simulations of each base-case and PSA model type were run to assess variability in
platform efficiency. RESULTS: The speed of Excel could not be timed in the base-
case microsimulation since results were calculated instantly. VBA was slower than
R with means of 0.09 seconds and 0.02 seconds, respectively. Java generated a
system time of zero, indicating the program required 0.001s. The Excel PSA sim-
ulations required the most time with 33.4s, followed by VBA (29.4s). R required
19.0s and Java required the least amount of time (4.0s). CPU usage for PSA simula-
tions was highest with Excel (80%) and similar for all other platforms (25%).
CONCLUSIONS:With the obvious caveats that program speed is a function of com-
puting power and coding efficiency, the results of this analysis demonstrate Java
was consistently faster than Excel, VBA and R, which are commonly used for phar-
macoeconomic models. With increasing model complexity and running times, ex-
ploration of alternate implementations for their execution is recommended.
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The current recommendations for the conservative management of overactive
bladder symptoms and detrusor overactivity, given by NICE 2012, are pelvic floor
muscle training, bladder training, sacral nerve stimulation, mid-urethral tape and
antimuscarinic drugs- oxybutynin, darifenacin, solifenacin, tolterodine, and trop-
sium. More recently, emerging evidence suggests that Botulinum toxin type A is
also an effective intervention for overactive bladder and idiopathic detrusor over-
activity. Although a number of meta-analyses have been published reporting pair-
wise comparisons of the various interventions, to date no network meta-analysis
has been undertaken comparing all interventions simultaneously.OBJECTIVES: To
evaluate the clinical effectiveness of drug therapy, neuromodulation, botulinum
toxin, and behaviour therapy, in the prevention of overactive bladder symptoms
and detrusor overactivity.METHODS:Mixed treatment network meta-analyses for
the individual, and classes (i.e. behaviour, drugs etc.), of interventions using Win-
BUGS. The correlations between the interventions within a class were addressed by
conducting a mixed treatment network meta-analysis using a hierarchical model
structure. RESULTS: Evaluation of the class of interventions, i.e. ‘lumping’ individ-
ual interventions with classes, demonstrates an increased precision in the out-
come; however, categorising the interventions decreases the interpretability of the
results. At the individual intervention level, the sparseness of the data decreases
the precision of the estimates, but enables comparisons to be made between indi-
vidual interventions. The hierarchical model, allows both increased precision, due
to the utilisation of all of the available data, whilst still allowing comparisons to be
made between individual interventions both within and between classes.
CONCLUSIONS: Use of a hierarchical model increases the interpretability of the
mixed treatment network meta-analysis whilst maximising the precision in terms
of outcome. However, defining the hierarchical structure can prove difficult in
some instances, with potential comparators residing at different levels in the hi-
erarchy.
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OBJECTIVES: Cost-effectiveness studies of health technologies where data are ex-
trapolated from short term clinical trials to estimate results over appropriate de-
cision making time horizons typically assume that the decision context remains
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